About Mainline Biosciences
Mainline Biosciences is specialized in research and development of novel peptide drugs for treatment of cancer. We have developed CXCR4 and peptide drug conjugate (PDC) platforms that will address major unmet medical needs.
The PDC platform is a new class of cancer therapy that overcomes major shortcomings of current therapies while delivering highly effective anti-tumor activity for breast, lung, liver, colon, pancreatic, ovarian, leukemia, etc. Our lead PDC drug candidate MLB1707 has demonstrated rapid and significant tumor growth reduction in multiple efficacy studies using triple negative breast cancer (TNBC) animal models.
The CXCR4 platform consists of MLB010 and MLB014, which are CXCR4 antagonists for treatment of multiple types of cancer. MLB010 is among the most potent known CXCR4 antagonists and substantially blocks SDF-1-induced cancer cell migration and invasion. MLB014 is a CXCR4 antagonist for acute myeloid leukemia (AML). MLB010 and MLB014 have shown excellent efficacy in inhibiting primary tumor growth in mice and excellent PK/PD profile enabling convenient once-daily therapy and oral dose potential. The CXCR4 antagonists are also superior combination therapy agents with anti-VEGF, PD-1 or PD-L1 antibodies.